The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

August 16, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
  • Do not start certolizumab during an active infection. If an infection develops, monitor carefully and stop certolizumab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on certolizumab, consider empiric anti-fungal therapy for those at high risk who reside in or travel to regions where mycoses, such as histoplasmosis, coccidioidomycosis or blastomycosis, are endemic.
  • Cases of lymphoma and other malignancies have been observed in patients receiving TNFi’s.
  • Heart failure, worsening or new onset, may occur.
  • Anaphylaxis or serious allergic reactions may occur.
  • HBV reactivation can occur; test for HBV infection before starting certolizumab. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop certolizumab and begin anti-viral therapy.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Cytopenias, pancytopenia—advise patients to seek immediate medical attention if symptoms develop, and consider stopping certolizumab.
  • Lupus-like syndrome—stop certolizumab if the syndrome develops.

Strategies to achieve remission &/or low disease activity include initiating disease-modifying anti-rheumatic drug therapy early in the disease course to slow & prevent joint damage.

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Explore This Issue
August 2019

Dosage & Administration

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Certolizumab is administered by SQ injection. The recommended initial dose is 400 mg (two SQ injections of 200 mg each) and 400 mg at Weeks 2 and 4, followed by 200 mg every other week. A maintenance dose of 400 mg every four weeks can be considered.

Commentary

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA approval was based on clinical trials that enrolled more than 2,300 patients. The results showed RA patients taking Cimzia with MTX had a greater reduction in signs and symptoms of RA after 24 weeks of treatment than patients taking only MTX. Some patients showed clinical responses to certolizumab plus MTX within one to two weeks. The most common adverse reactions (≥7%) were upper respiratory tract infection, rash and urinary tract infection.

Etanercept (Enbrel):14 injection

Biosimilars: etanercept-szzs (Erelzi),15 etanercept-ykro (Eticovo)16

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (p. 14)

Warnings & Precautions

  • Do not start etanercept during an active infection. If an infection develops, monitor carefully and stop etanercept if the infection becomes serious.
  • Consider empiric anti-fungal therapy for patients at high risk (those who reside in or travel to regions where mycoses, such as histoplasmosis, coccidioidomycosis or blastomycosis, are endemic) of invasive fungal infections who develop a severe systemic illness on etanercept.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Cases of lymphoma have been observed in patients receiving TNFi’s.
  • Congestive heart failure, worsening or new onset, may occur.
  • Advise patients to seek immediate medical attention if symptoms of pancytopenia or aplastic anemia develop, and consider stopping etanercept.
  • Monitor HBV carriers for reactivation during and following therapy. If reactivation occurs, consider stopping etanercept and beginning anti-viral therapy.
  • Anaphylaxis or serious allergic reactions may occur.
  • Stop etanercept if lupus-like syndrome or autoimmune hepatitis develops.

Dosage & Administration

Etanercept is administered by SQ injection. The recommended initial dose is 50 mg once weekly with or without MTX.

Commentary

Etanercept was the first TNFi approved for the treatment of RA. The results of the clinical trials have demonstrated its clinical safety and efficacy in early, as well as established, disease. Patients with RA on etanercept were found to not only have reduced disease activity, but also have limited progression of joint damage in early and late disease. Etanercept can be used as a monotherapy or in combination with MTX, although the combination therapy appears to be more effective in terms of reducing joint damage. The most common adverse reactions (≥5%) were infections and injection-site reactions.

Golimumab (Simponi):17 injection

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (p. 14)

Warnings & Precautions

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: abatacept, adalimumab, anakinra, baricitinib, Certolizumab Pegol, etanercept, Golimumab, infliximab, rituximab, sarilumab, tocilizumab, TofacitinibIssue: August 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
  • Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)